Literature DB >> 7438685

Buprenorphine kinetics.

R E Bullingham, H J McQuay, A Moore, M R Bennett.   

Abstract

Buprenorphine kinetics was determined in surgical patients using radioimmunoassay. Buprenorphine was measured in the plasma of 24 patients who had received 0.3 mg buprenorphine intraoperatively. After 3 hr 10 of these patients then received a further 0.3 mg buprenorphine intravenously for postoperative pain relief, and 11 patients were given 0.3 mg intramuscularly; again, plasma levels were measured for 3 hr. The data fitted closely to a triexponential decay curve. There was a very fast initial phase, with a half-life (t1/2) of 2 min. The terminal t1/2 was slow, approximately 3 hr. Comparison of the kinetics of the same patient, awake and anesthetized, showed that the clearance was significantly lower in the anesthetized state. A notable feature of the drug given intramuscularly is rapid systemic availability, so that peaks are obtained in 2 to 5 min, and in 10 min the resulting levels are the same as for the intravenous and intramuscular routes.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7438685     DOI: 10.1038/clpt.1980.219

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  37 in total

Review 1.  Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence.

Authors:  Alexander Elkader; Beth Sproule
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

2.  Population pharmacokinetics of buprenorphine following a two-stage intravenous infusion in healthy volunteers.

Authors:  Mette L Jensen; David J R Foster; Richard N Upton; Kim Kristensen; Steen H Hansen; Niels-Henrik Jensen; Bettina N Nielsen; Ulrik Skram; Hanne H Villesen; Lona Christrup
Journal:  Eur J Clin Pharmacol       Date:  2007-09-16       Impact factor: 2.953

3.  [Not Available].

Authors:  I Jurna
Journal:  Schmerz       Date:  1987-07       Impact factor: 1.107

Review 4.  Pharmacokinetics of opioids in liver disease.

Authors:  I Tegeder; J Lötsch; G Geisslinger
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

5.  Abuse potential of intranasal buprenorphine versus buprenorphine/naloxone in buprenorphine-maintained heroin users.

Authors:  Jermaine D Jones; Maria A Sullivan; Suzanne K Vosburg; Jeanne M Manubay; Shanthi Mogali; Verena Metz; Sandra D Comer
Journal:  Addict Biol       Date:  2014-07-25       Impact factor: 4.280

6.  Population Pharmacokinetic Model of Sublingual Buprenorphine in Neonatal Abstinence Syndrome.

Authors:  Chee M Ng; Erin Dombrowsky; Hopi Lin; Michelle E Erlich; David E Moody; Jeffrey S Barrett; Walter K Kraft
Journal:  Pharmacotherapy       Date:  2015-07-14       Impact factor: 4.705

7.  Evaluation of the clearance of a sublingual buprenorphine spray in the beagle dog using gamma scintigraphy.

Authors:  Fiona McInnes; Nicola Clear; Gerry James; Howard N E Stevens; Unai Vivanco; Michael Humphrey
Journal:  Pharm Res       Date:  2007-09-01       Impact factor: 4.200

Review 8.  Clinical pharmacokinetics and pharmacodynamics of opioid analgesics in infants and children.

Authors:  K T Olkkola; K Hamunen; E L Maunuksela
Journal:  Clin Pharmacokinet       Date:  1995-05       Impact factor: 6.447

9.  Intravenous buprenorphine and norbuprenorphine pharmacokinetics in humans.

Authors:  M A Huestis; E J Cone; S O Pirnay; A Umbricht; K L Preston
Journal:  Drug Alcohol Depend       Date:  2012-12-14       Impact factor: 4.492

10.  The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data.

Authors:  W O Farid; S A Dunlop; R J Tait; G K Hulse
Journal:  Curr Neuropharmacol       Date:  2008-06       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.